Trials / Completed
CompletedNCT01653444
Evaluate the Safety and Exploratory Efficacy of GC1119
Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119(Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- Male
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119 (recombinant human α-galactosidase A) for enzyme replacement therapy in Fabry disease patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GC1119 | biweekly, IV infusion |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2014-05-01
- Completion
- 2015-10-01
- First posted
- 2012-07-31
- Last updated
- 2016-06-24
Locations
3 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01653444. Inclusion in this directory is not an endorsement.